Seeing Is Believing
Currently out of the existing stock ratings of Colin Bristow, 61 are a BUY (56.48%), 47 are a HOLD (43.52%).
Analyst Colin Bristow, currently employed at UBS, carries an average stock price target met ratio of 56.65% that have a potential upside of 14.86% achieved within 194 days.
Colin Bristow’s has documented 216 price targets and ratings displayed on 21 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on AMGN, Amgen at 03-May-2024.
Analyst best performing recommendations are on IMVT (IMMUNOVANT ).
The best stock recommendation documented was for IMVT (IMMUNOVANT ) at 9/26/2022. The price target of $5 was fulfilled within 3 days with a profit of $0.48 (10.62%) receiving and performance score of 35.4.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Time (Days) For PT To Be Met
Performance score
Buy
205
$22.5 (12.33%)
3 years 2 months 21 days ago
3/5 (60%)
$35.09 (20.65%)
938
Hold
173
$-9.5 (-5.21%)
156
3 years 2 months 23 days ago
14/24 (58.33%)
$2.73 (1.60%)
682
Hold
190
$7.5 (4.11%)
194
3 years 5 months 22 days ago
9/11 (81.82%)
$34.41 (22.12%)
350
Hold
166
$-16.5 (-9.04%)
175
3 years 5 months 22 days ago
23/23 (100%)
$10.41 (6.69%)
828
Buy
155
3 years 6 months 19 days ago
7/7 (100%)
$36.79 (31.12%)
395
Which stock is Colin Bristow is most bullish on?
Which stock is Colin Bristow is most reserved on?
What Year was the first public recommendation made by Colin Bristow?